Neurosurgery at Nanjing Drum Tower Hospital and Nanjing University, China
Dr. Zheng Peng, affiliated with the Department of Neurosurgery at Nanjing Drum Tower Hospital and Nanjing University, is a dedicated researcher in the field of subarachnoid hemorrhage. A graduate of Nanjing University, he focuses on understanding and treating this condition. His pioneering research has demonstrated that hydrogen can inhibit ferroptosis, a form of cell death, thus offering neuroprotective benefits. Dr. Peng’s work has advanced the clinical application of hydrogen therapy, particularly in regulating lactic acid metabolism and reducing neuroinflammation. He has published multiple research papers and collaborates with prominent scientists, making significant contributions to medical science.
Professional Profiles
Academic and Professional Background
Zheng Peng, a graduate of Nanjing University, is committed to investigating the pathophysiological mechanisms and treatment of subarachnoid hemorrhage. His research has revealed that hydrogen exhibits the capacity to inhibit ferroptosis and has advanced the clinical application of hydrogen in treatment.
Research and Innovations
Hydrogen inhalation therapy regulates lactic acid metabolism following subarachnoid hemorrhage through the HIF-1α pathway Hydrogen exerts neuroprotective effects after subarachnoid hemorrhage by attenuating neuronal ferroptosis and inhibiting neuroinflammation
Research Focuse
Dr. Zheng Peng is an expert in the field of neuroscience, with a primary research focus on the treatment and pathophysiology of subarachnoid hemorrhage (SAH). His work emphasizes the neuroprotective effects of hydrogen therapy, particularly its role in mitigating neuronal ferroptosis and neuroinflammation. Dr. Peng has also investigated the impact of mitochondrial dysfunction and quality control in SAH. His research contributions include demonstrating the therapeutic potential of menaquinone-4 in reducing ferroptosis and using neuron-targeted liposomal coenzyme Q10 to protect neurons. Through his studies, Dr. Peng aims to develop innovative treatments to improve outcomes for patients with SAH.
Publications
- Corrigendum to “Neuron-targeted liposomal coenzyme Q10 attenuates neuronal ferroptosis after subarachnoid hemorrhage by activating the ferroptosis suppressor protein 1/coenzyme Q10 system” Acta Biomaterialia 2024, 179:325-339, Publication date: 2024.
- P38-DAPK1 axis regulated LC3-associated phagocytosis (LAP) of microglia in an in vitro subarachnoid hemorrhage model, Publication date: 2023.
- Menaquinone-4 attenuates ferroptosis by upregulating DHODH through activation of SIRT1 after subarachnoid hemorrhage, Publication date: 2024.
- Inhibition of USP30 Promotes Mitophagy by Regulating Ubiquitination of MFN2 by Parkin to Attenuate Early Brain Injury After SAH, Publication date: 2023.
- Novel perfluorocarbon-based oxygenation therapy alleviates Post-SAH hypoxic brain injury by inhibiting HIF-1α, Publication date: 2024.
- Hydrogen exerts neuroprotective effects after subarachnoid hemorrhage by attenuating neuronal ferroptosis and inhibiting neuroinflammation, Publication date: 2024.
- Mitochondrial dysfunction and quality control lie at the heart of subarachnoid hemorrhage, Publication date: 2024.
- Gender potentially affects early postoperative hyponatremia in pituitary adenoma: XGBoost-based predictive modeling, Publication date: 2024.
- Neuron-targeted liposomal coenzyme Q10 attenuates neuronal ferroptosis after subarachnoid hemorrhage by activating the ferroptosis suppressor protein 1/coenzyme Q10 system, Publication date: 2024.
.